Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds

doi:10.1016/0163-7258(95)00017-B

Pharmacology & Therapeutics

Volume 67, Issue 2, 1995, Pages 247-281

https://doi.org/10.1016/0163-7258(95)00017-B Get rights and content

Abstract

The aryl hydrocarbon (Ah) receptor binds several different structural classes of chemicals, including halogenated aromatics, typified by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), polynuclear aromatic and heteropolynuclear aromatic hydrocarbons. TCDD induces expression of several genes including CYP1A1, and molecular biology studies show that the Ah receptor acts as a nuclear ligand-induced transcription factor that interacts with xenobiotic or dioxin responsive elements located in 5′-flanking regions of responsive genes. TCDD also elicits diverse toxic effects, modulates endocrine pathways and inhibits a broad spectrum of estrogen (17β-estradiol)-induced responses in rodents and human breast cancer cell lines. Molecular biology studies show that TCDD inhibited 17β-estradiol-induced cathepsin D gene expression by targeted interaction of the nuclear Ah receptor with imperfect dioxin responsive elements strategically located within the estrogen receptor — Spl enhancer sequence of this gene.

References (333)

D.C. Asman et al.
Organization and characterization of the rat class 3 aldehyde dehydrogenase gene
J. Biol. Chem.
(1993)
B. Astroff et al.
Comparative antiestrogenic activities of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 6-methyl-1,3,8-trichlorodibenzofuran in the female rat
Toxicol. Appl. Pharmacol.
(1988)
B. Astroff et al.
6-Substituted-1,3,8-trichlorodibenzofurans as 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonists in the rat: structure-activity relationships
Toxicology
(1989)
B. Astroff et al.
2,3,7,8-Tetrachlorodibenzo-p-dioxin as an antiestrogen: effect on rat uterine peroxidase activity
Biochem. Pharmacol.
(1990)
B. Astroff et al.
6-Alkyl-1,3,8-trichlorodibenzofurans as antiestrogens in female Sprague-Dawley rats
Toxicology
(1991)
B. Astroff et al.
2,3,7,8-Tetrachlorodibenzo-p-dioxin inhibition of 17β-estradiol-induced increases in rat uterine EGF receptor binding activity and gene expression
Mol. Cell. Endocrinol.
(1990)
B. Astroff et al.
Inhibition of 17β-estradiol-induced and constitutive expression of the cellular protooncogene c-fos by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the female uterus
Toxicol. Lett.
(1991)
J.G. Babish et al.
Effect of dietary indole-3-carbinol on the induction of the mixed-function oxidases of rat tissue
Food Cosmet. Toxicol.
(1978)
P.A. Bank et al.
Species-specific binding of transformed Ah receptor to a dioxin responsive transcriptional enhancer
Eur. J. Pharmacol.
(1992)
R. Bannister et al.
6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonists in C57BL/6 mice
Toxicology
(1989)

C.W. Barker et al.

Interleukin-1beta suppresses the induction of P4501A1 and P4501A2 messenger RNAs in isolated hepatocytes

J. Biol. Chem.

(1992)

C.W. Barker et al.

Down-regulation of P4501A1 and P4501A2 mRNA expression in isolated hepatocytes by oxidative stress

J. Biol. Chem.

(1994)

L.L. Bestervelt et al.

TCDD alters pituitary-adrenal function I: adrenal responsiveness to exogenous ACTH

Neurotoxicol. Teratol.

(1993)

L.L. Bestervelt et al.

TCDD alters pituitary-adrenal function II: evidence for decreased bioactivity of ACTH

Neurotoxicol. Teratol.

(1993)

L. Biegel et al.

Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on cell growth and the secretion of the estrogen-induced 34-, 52- and 160-kDa proteins in human breast cancer cells

J. Steroid Biochem. Mol. Biol.

(1990)

P.D. Boucher et al.

Specific nuclear protein binding to a negative regulatory element on the human CYP1A1 gene

J. Biol. Chem.

(1993)

N.J. Bunce et al.

Kinetic models for association of 2,3,7,8-tetrachlorodibenzo-p-dioxin with the Ah receptor

Arch. Biochem. Biophys.

(1988)

H.R. Buser et al.

Polychlorinated dibenzofurans (PCDFs) found in Yusho oil and in used Japanese PCB

Chemosphere

(1978)

V. Cavailles et al.

Cathepsin D gene of human MCF-7 cells contains estrogen-responsive sequences in its 5′-proximal flanking region

Biochem. Biophys. Res. Commun.

(1991)

K. Chaloupka et al.

Synergistic activity of aromatic hydrocarbon mixtures as aryl hydrocarbon (Ah) receptor agonists

Chem. Biol. Interact.

(1993)

H. Chen et al.

Subunit composition of the heteromeric cytosolic aryl hydrocarbon receptor complex

J. Biol. Chem.

(1994)

E.J. Choi et al.

Dioxin induced transforming growth factor-α in human keratinocytes

J. Biol. Chem.

(1991)

S.M.F. de Morais et al.

Photoaffinity labeling of the Ah receptor with 3-[³H]methylcholanthrene and formation of a 165-kDa complex between the ligand-binding subunit and a novel cytosolic protein

J. Biol. Chem.

(1994)

M.S. Denison et al.

Hepatic Ah receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin: partial stabilization by molybdate

J. Biol. Chem.

(1986)

M.S. Denison et al.

The DNA recognition site for the dioxin-Ah receptor complex

J. Biol. Chem.

(1988)

M.S. Denison et al.

Protein-DNA interactions at recognition sites for the dioxin-Ah receptor complex

J. Biol. Chem.

(1989)

M.J. DeVito et al.

Antiestrogenic action of 2,3,7,8-tetrachlorodibenzo-p-dioxin: tissue-specific regulation of estrogen receptor in CD1 mice

Toxicol. Appl. Pharmacol.

(1992)

C.J. Elferink et al.

2,3,7,8-Tetrachlorodibenzo-p-dioxin-inducible, Ah receptor-mediated bending of enhancer DNA

J. Biol. Chem.

(1990)

C.J. Elferink et al.

Protein-DNA interactions at a dioxin-responsive enhancer. Evidence that the transformed Ah receptor is heteromeric

J. Biol. Chem.

(1990)

M. Ema et al.

cDNA cloning and structure of the putative Ah receptor

Biochem. Biophys. Res. Commun.

(1992)

M. Ema et al.

Dioxin binding activities of polymorphic forms of mouse and human aryl hydrocarbon receptors

J. Biol. Chem.

(1994)

J.B. Fagan et al.

Noncoordinate regulation of the mRNAs encoding cytochromes P-450_BNF/MC-B and P-450_1SF/BNF-G

Arch. Biochem. Biophys.

(1986)

K. Farrell et al.

Synthesis and aryl hydrocarbon receptor binding properties of radiolabeled polychlorinated dibenzofuran congeners

Arch. Biochem. Biophys.

(1987)

P. Fernandez et al.

Growth inhibitory and antimitogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in T47D human breast cancer cells

Toxicol. Lett.

(1992)

Y. Fukuda et al.

Suppression of cytochrome P4501A1 by interleukin-6 in human HepG2 hepatoma cells

Biochem. Pharmacol.

(1994)

K.W. Gaido et al.

Regulation of gene expression and acceleration of differentiation in human keratinocytes by 2,3,7,8-tetrachlorodibenzo-p-dioxin

Toxicol. Appl. Pharmacol.

(1994)

K.W. Gaido et al.

2,3,7,8-Tetrachlorodibenzo-p-dioxin-dependent regulation of transforming growth factors-α and β₂ expression in a human keratinocyte cell line involves both transcriptional and post-transcriptional control

J. Biol. Chem.

(1992)

M.A. Gallo et al.

Interactive effects of estradiol and 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic cytochrome P-450 and mouse uterus

Toxicol. Lett.

(1986)

J.F. Gierthy et al.

Enhancement of 2- and 16α-estradiol hydroxylation in MCF-7 human breast cancer cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin

Biochem. Biophys. Res. Commun.

(1988)

J.A. Goldstein et al.

Mechanism of action and structure-activity relationships for the chlorinated dibenzo-p-dioxins and related compounds

K. Gradin et al.

Nonresponsiveness of normal human fibroblasts to dioxin correlates with the presence of a constitutive xenobiotic response element-binding factor

J. Biol. Chem.

(1993)

N. Guilbaud et al.

Modulation of estrogen receptors by phorbol diesters in human breast MCF-7 cell line

Mol. Cell. Endocrinol.

(1988)

M.E. Hahn et al.

The Ah receptor in marine animals: phylogenetic distribution and relationship to cytochrome P4501A inducibility

Mar. Environ. Res.

(1992)

O. Hankinson et al.

Genetic and molecular analysis of the Ah receptor and of Cyp1a-1 gene expression

Biochimie

(1991)

J.R. Allen et al.

Light and electron microscopic observations in Macaca mulatta monkeys fed toxic fat

Am. J. Vet. Res.

(1967)

J.R. Allen et al.

Response of chickens to prolonged feeding of crude toxic fat

Y. Aoki et al.

Induction of glutathione S-transferase P-form in primary cultured rat liver parenchymal cells by co-planar polychlorinated biphenyl congeners

Biochem. J.

(1992)

L.O. Arellano et al.

Effects of cycloheximide on the induction of CYP1A1 gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in three human breast cancer cell lines

Carcinogenesis

(1993)

B. Astroff et al.

6-Methyl-1,3,8-trichlorodibenzofuran as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist: inhibition of the induction of rat cytochrome P-450 isozymes and related monooxygenase activities

Mol. Pharmacol.

(1988)

C.H. Bastomsky

Enhanced thyroxine metabolism and high uptake goiters in rats after a single dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin

Endocrinology

(1977)

Cited by (332)

Advances in polychlorinated biphenyls-induced female reproductive toxicity
2024, Science of the Total Environment
Polychlorinated biphenyls (PCBs) are a class of endocrine-disrupting chemicals (EDCs) widely present in the environment. PCBs have been of concern due to their anti/estrogen-like effects, which make them more toxic to the female reproductive system. However, there is still a lack of systematic reviews on the reproductive toxicity of PCBs in females, so the adverse effects and mechanisms of PCBs on the female reproductive system were summarized in this paper. Our findings showed that PCBs are positively associated with lower pregnancy rate, hormone disruption, miscarriage and various reproductive diseases in women. In animal experiments, PCBs can damage the structure and function of the ovaries, uterus and oviducts. Also, PCBs could produce epigenetic effects and be transferred to the offspring through the maternal placenta, causing development retardation, malformation and death of embryos, and damage to organs of multiple generations. Furthermore, the mechanisms of PCBs-induced female reproductive toxicity mainly include receptor-mediated hormone disorders, oxidative stress, apoptosis, autophagy, and epigenetic modifications. Finally, we also present some directions for future research on the reproductive toxicity of PCBs. This detailed information provided a valuable reference for fully understanding the reproductive toxicity of PCBs.
DESIGNER fraction concept unmasks minor bioactive constituents in red clover (Trifolium pratense L.)
2023, Phytochemistry
In botanical extracts, highly abundant constituents can mask or dilute the effects of other, and often, more relevant biologically active compounds. To facilitate the rational chemical and biological assessment of these natural products with wide usage in human health, we introduced the DESIGNER approach of Depleting and Enriching Selective Ingredients to Generate Normalized Extract Resources. The present study applied this concept to clinical Red Clover Extract (RCE) and combined phytochemical and biological methodology to help rationalize the utility of RCE supplements for symptom management in postmenopausal women. Previous work has demonstrated that RCE reduces estrogen detoxification pathways in breast cancer cells (MCF-7) and, thus, may serve to negatively affect estrogen metabolism-induced chemical carcinogenesis. Clinical RCE contains ca. 30% of biochanin A and formononetin, which potentially mask activities of less abundant compounds. These two isoflavonoids are aryl hydrocarbon receptor (AhR) agonists that activate P450 1A1, responsible for estrogen detoxification, and P450 1B1, producing genotoxic estrogen metabolites in female breast cells. Clinical RCE also contains the potent phytoestrogen, genistein, that downregulates P450 1A1, thereby reducing estrogen detoxification. To identify less abundant bioactive constituents, countercurrent separation (CCS) of a clinical RCE yielded selective lipophilic to hydrophilic metabolites in six enriched DESIGNER fractions (DFs 01–06). Unlike solid-phase chromatography, CCS prevented any potential loss of minor constituents or residual complexity (RC) and enabled the polarity-based enrichment of certain constituents. Systematic analysis of estrogen detoxification pathways (ERα-degradation, AhR activation, CYP1A1/CYP1B1 induction and activity) of the DFs uncovered masked bioactivity of minor/less abundant constituents including irilone. These data will allow the optimization of RCE with respect to estrogen detoxification properties. The DFs revealed distinct biological activities between less abundant bioactives. The present results can inspire future carefully designed extracts with phytochemical profiles that are optimized to increase in estrogen detoxification pathways and, thereby, promote resilience in women with high-risk for breast cancer. The DESIGNER approach helps to establish links between complex chemical makeup, botanical safety and possible efficacy parameters, yields candidate DFs for (pre)clinical studies, and reveals the contribution of minor phytoconstituents to the overall safety and bioactivity of botanicals, such as resilience promoting activities relevant to women's health.
The aryl hydrocarbon receptor in immune regulation and autoimmune pathogenesis
2023, Journal of Autoimmunity
As a ligand-activated transcription factor, the aryl hydrocarbon receptor (AhR) is activated by structurally diverse ligands derived from the environment, diet, microorganisms, and metabolic activity. Recent studies have demonstrated that AhR plays a key role in modulating both innate and adaptive immune responses. Moreover, AhR regulates innate immune and lymphoid cell differentiation and function, which is involved in autoimmune pathogenesis. In this review, we discuss recent advances in understanding the mechanism of activation of AhR and its mediated functional regulation in various innate immune and lymphoid cell populations, as well as the immune-regulatory effect of AhR in the development of autoimmune diseases. In addition, we highlight the identification of AhR agonists and antagonists that may serve as potential therapeutic targets for the treatment of autoimmune disorders.
Effects of short-chain per- and polyfluoroalkyl substances (PFAS) on human cytochrome P450 (CYP450) enzymes and human hepatocytes: An in vitro study
2023, Current Research in Toxicology
Short-chain per- and polyfluoroalkyl substances (PFAS) have been developed as alternatives to legacy long-chain PFAS, but they may still pose risks due to their potential to interact with biomolecules. Cytochrome P450 (CYP450) enzymes are essential for xenobiotic metabolism, and disruptions of these enzymes by PFAS can have significant human health implications. The inhibitory potential of two legacy long-chain (PFOA and PFOS) and five short-chain alternative PFAS (PFBS, PFHxA, HFPO-DA, PFHxS, and 6:2 FTOH) were assessed in recombinant CYP1A2, − 2B6, −2C19, −2E1, and −3A4 enzymes. Most of the short-chain PFAS, except for PFHxS, tested did not result in significant inhibition up to 100 μM. PFOS inhibited recombinant CYP1A2, −2B6, −2C19, and −3A4 enzymes. However, concentrations where inhibition occurred, were all higher than the averages reported in population biomonitoring studies, with IC₅₀ values higher than 10 µM. We also evaluated the activities of CYP1A2 and CYP3A4 in HepaRG monolayers following 48 h exposures of the short-chain PFAS at two concentrations (1 nM or 1 µM) and with or without an inducer (benzo[a]pyrene, BaP, for CYP1A2 and rifampicin for CYP3A4). Our findings suggest that both 1 nM and 1 µM exposures to short-chain PFAS can modulate the CYP1A2 activity induced by BaP. Except for PFHxS, the short-chain PFAS appear to have little effect on CYP3A4 activity. Understanding the effects of PFAS exposure on biotransformation can shed light on the mechanisms of PFAS toxicity and aid in developing effective strategies for managing chemical risks, enabling regulators to make more informed decisions.
Killing two birds with one stone: Pregnancy is a sensitive window for endocrine effects on both the mother and the fetus
2022, Environmental Research
Pregnancy is a complex process requiring tremendous physiological changes in the mother in order to fulfill the needs of the growing fetus, and to give birth, expel the placenta and nurse the newborn. These physiological modifications are accompanied with psychological changes, as well as with variations in habits and behaviors. As a result, this period of life is considered as a sensitive window as impaired functional and physiological changes in the mother can have short- and long-term impacts on her health. In addition, dysregulation of the placenta and of mechanisms governing placentation have been linked to chronic diseases later-on in life for the fetus, in a concept known as the Developmental Origin of Health and Diseases (DOHaD). This concept stipulates that any change in the environment during the pre-conception and perinatal (in utero life and neonatal) period to puberty, can be “imprinted” in the organism, thereby impacting the health and risk of chronic diseases later in life. Pregnancy is a succession of events that is regulated, in large part, by hormones and growth factors. Therefore, small changes in hormonal balance can have important effects on both the mother and the developing fetus. An increasing number of studies demonstrate that exposure to endocrine disrupting compounds (EDCs) affect both the mother and the fetus giving rise to growing concerns surrounding these exposures. This review will give an overview of changes that happen during pregnancy with respect to the mother, the placenta, and the fetus, and of the current literature regarding the effects of EDCs during this specific sensitive window of exposure.
Anti-tumor properties of methoxylated analogues of resveratrol in malignant MCF-7 but not in non-tumorigenic MCF-10A mammary epithelial cell lines
2019, Toxicology
Resveratrol is a plant-derived polyphenol that is known for its anti-inflammatory and anti-tumorigenic properties in in vitro and in vivo models. Recent studies show that some resveratrol analogues might be more potent anti-tumor agents, which may partly be attributed to their ability to activate the aryl hydrocarbon receptor (AHR). Here, the anti-tumorigenic properties of resveratrol and structural analogues oxyresveratrol, pinostilbene, pterostilbene and tetramethoxystilbene (TMS) were studied in vitro, using in the malignant human MCF-7 breast cancer cell line and non-tumorigenic breast epithelial cell line MCF-10A.
Cell viability and migration assays showed that methoxylated analogues of resveratrol are more potent anti-tumorigenic compounds than resveratrol and its hydroxylated analogue oxyresveratrol, with 2,3’,4,5’-tetramethoxy-trans-stilbene (TMS) being the most potent compound. TMS decreased MCF-7 tumor cell viability with 50% at 3.6 μM and inhibited migration with 37.5 ± 14.8% at 3 μM. In addition, TMS activated the AHR more potently (EC50 in a reporter gene assay 2.0 μM) and induced AHR-mediated induction of cytochrome P450 1A1 (CYP1A1) activity (EC50 value of 0.7 μM) more than resveratrol and the other analogues tested. Cell cycle analysis showed that TMS induced a shift in cell cycle status from the G1 to the G2/M phase causing a cell cycle arrest in the MCF-7 cells, while no effect of TMS was observed in the non-tumorigenic MCF-10A mammary epithelial cell line. Gene expression analysis showed that 3 μM TMS increased gene expression of CYP1A1 (289-fold), CYP1B1 (5-fold) and Nqo1 (2-fold), and decreased gene expression of IL-8 (3-fold) in MCF-7 cells. In MCF-10A cells, 10 μM TMS also increased gene expression of CYP1A1 (5-fold) and CYP1B1 (2-fold), but decreased gene expression of Nqo1 (1.4-fold) in contrast to MCF-7 cells.
TMS displays more potent anti-tumorigenic properties and activates the AHR more effectively than resveratrol. In addition, this is the first study to show that TMS, but not resveratrol, selectively inhibits the cell cycle of breast tumor cells and not the non-tumorigenic cells. Our study provides more insight in the anti-tumor properties of the methoxylated analogues of resveratrol in breast cells in vitro.

View all citing articles on Scopus

View full text

Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds

Abstract

J. Biol. Chem.

Toxicol. Appl. Pharmacol.

Toxicology

Biochem. Pharmacol.

Toxicology

Mol. Cell. Endocrinol.

Toxicol. Lett.

Food Cosmet. Toxicol.

Eur. J. Pharmacol.

Toxicology

J. Biol. Chem.

J. Biol. Chem.

Neurotoxicol. Teratol.

Neurotoxicol. Teratol.

J. Steroid Biochem. Mol. Biol.

J. Biol. Chem.

Arch. Biochem. Biophys.

Chemosphere

Biochem. Biophys. Res. Commun.

Chem. Biol. Interact.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Toxicol. Appl. Pharmacol.

J. Biol. Chem.

J. Biol. Chem.

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

Arch. Biochem. Biophys.

Arch. Biochem. Biophys.

Toxicol. Lett.

Biochem. Pharmacol.

Toxicol. Appl. Pharmacol.

J. Biol. Chem.

Toxicol. Lett.

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

Mol. Cell. Endocrinol.

Mar. Environ. Res.

Biochimie

Light and electron microscopic observations in Macaca mulatta monkeys fed toxic fat

Am. J. Vet. Res.

Response of chickens to prolonged feeding of crude toxic fat

Induction of glutathione S-transferase P-form in primary cultured rat liver parenchymal cells by co-planar polychlorinated biphenyl congeners

Biochem. J.

Effects of cycloheximide on the induction of CYP1A1 gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in three human breast cancer cell lines

Carcinogenesis

6-Methyl-1,3,8-trichlorodibenzofuran as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist: inhibition of the induction of rat cytochrome P-450 isozymes and related monooxygenase activities

Mol. Pharmacol.

Enhanced thyroxine metabolism and high uptake goiters in rats after a single dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin

Endocrinology